GlassScriptPhysician profile
Sabiha Rasheed
NPI 1134161524
$2,076.15
in general payments reported to CMS, 2019-2025
13 companies · $553 in 2025
The $553 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197 · 2020: $36.94 · 2021: $15.42 · 2022: $325 · 2023: $578 · 2024: $371 · 2025: $553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,425 · Education: $76.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,424.81 |
| Education | $76.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $520.85 | 2023-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $456.31 | 2019-2025 | |
| Amgen INC. | $407.18 | 2019-2025 | Enbrel, Evenity, Tavneos |
| Janssen Biotech, INC. | $337.38 | 2019-2025 | Tremfya, Stelara |
| Glaxosmithkline, LLC. | $76.15 | 2019-2025 | Benlysta, Trelegy Ellipta |
| Kiniksa Pharmaceuticals, LTD. | $75.25 | 2023 | Arcalyst |
| Alexion Pharmaceuticals, INC. | $56.74 | 2022 | |
| Horizon Therapeutics Plc | $46.84 | 2020-2023 | |
| Novartis Pharmaceuticals Corporation | $32.41 | 2023 | |
| Aurinia Pharma U.S., INC. | $26.08 | 2023 | Lupkynis |
| Celgene Corporation | $16.16 | 2019 | |
| Genzyme Corporation | $13.28 | 2019 | |
| Pfizer INC. | $11.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sabiha Rasheed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.